

# E Dianne Pulte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8728681/publications.pdf>

Version: 2024-02-01

66  
papers

3,319  
citations

218677

26  
h-index

144013

57  
g-index

66  
all docs

66  
docs citations

66  
times ranked

5276  
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. <i>Oncologist</i> , 2010, 15, 994-1001.	3.7	623
2	Recent major improvement in long-term survival of younger patients with multiple myeloma. <i>Blood</i> , 2008, 111, 2521-2526.	1.4	495
3	Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. <i>Blood</i> , 2009, 113, 1408-1411.	1.4	202
4	Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. <i>Blood</i> , 2008, 111, 4916-4921.	1.4	133
5	Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data. <i>Oncologist</i> , 2011, 16, 1600-1603.	3.7	131
6	Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. <i>Haematologica</i> , 2009, 94, 270-275.	3.5	113
7	Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990-2004. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1301-1309.	6.3	107
8	Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. <i>Blood</i> , 2008, 111, 2977-2983.	1.4	103
9	Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. <i>Haematologica</i> , 2008, 93, 594-600.	3.5	99
10	Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. <i>Haematologica</i> , 2013, 98, 222-229.	3.5	86
11	Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States. <i>PLoS ONE</i> , 2014, 9, e85554.	2.5	86
12	Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. <i>Leukemia and Lymphoma</i> , 2014, 55, 1083-1089.	1.3	82
13	Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. <i>British Journal of Haematology</i> , 2015, 171, 189-196.	2.5	80
14	Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century. <i>Archives of Internal Medicine</i> , 2008, 168, 469.	3.8	78
15	Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. <i>Blood Cancer Journal</i> , 2020, 10, 56.	6.2	67
16	CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 367-372.	0.4	63
17	Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. <i>Cancer</i> , 2009, 115, 4973-4979.	4.1	56
18	Changes in the survival of older patients with hematologic malignancies in the early 21st century. <i>Cancer</i> , 2016, 122, 2031-2040.	4.1	46

#	ARTICLE	IF	CITATIONS
19	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation. <i>Clinical Cancer Research</i> , 2021, 27, 3515-3521.	7.0	42
20	Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. <i>Journal of Hematology and Oncology</i> , 2016, 9, 28.	17.0	40
21	FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. <i>Oncologist</i> , 2018, 23, 1366-1371.	3.7	40
22	Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. <i>Haematologica</i> , 2008, 93, 1544-1549.	3.5	39
23	Subsite-specific colorectal cancer risk in the colorectal endoscopy era. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 621-630.e1.	1.0	39
24	Survival of Patients with Chronic Myelocytic Leukemia: Comparisons of Estimates from Clinical Trial Settings and Population-Based Cancer Registries. <i>Oncologist</i> , 2011, 16, 663-671.	3.7	34
25	Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 538-546.	1.3	33
26	Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century. <i>European Journal of Haematology</i> , 2015, 94, 540-545.	2.2	29
27	Social disparities in survival after diagnosis with colorectal cancer: Contribution of race and insurance status. <i>Cancer Epidemiology</i> , 2017, 48, 41-47.	1.9	25
28	Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003–2014: a large international population-based study. <i>International Journal of Cancer</i> , 2018, 143, 3227-3239.	5.1	25
29	Survival Disparities by Insurance Type for Patients Aged 15–64 Years With Non-Hodgkin Lymphoma. <i>Oncologist</i> , 2015, 20, 554-561.	3.7	21
30	Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. <i>Journal of Hematology and Oncology</i> , 2013, 6, 70.	17.0	20
31	Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. <i>Leukemia and Lymphoma</i> , 2013, 54, 979-985.	1.3	20
32	Survival Expectations of Patients Diagnosed with Hodgkin's Lymphoma in 2006–2010. <i>Oncologist</i> , 2009, 14, 806-813.	3.7	19
33	Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008–2012. <i>Cancer Epidemiology</i> , 2012, 36, e19-e25.	1.9	19
34	Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. <i>Blood Advances</i> , 2018, 2, 116-119.	5.2	19
35	Age disparities in survival from lymphoma and myeloma: a comparison between US and England. <i>British Journal of Haematology</i> , 2014, 165, 824-831.	2.5	18
36	Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. <i>British Journal of Haematology</i> , 2014, 164, 851-857.	2.5	17

#	ARTICLE	IF	CITATIONS
37	Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults. <i>International Journal of Cancer</i> , 2016, 139, 1289-1296.	5.1	17
38	Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. <i>Leukemia and Lymphoma</i> , 2009, 50, 179-186.	1.3	16
39	Case series of octogenarians with sickle cell disease. <i>Blood</i> , 2016, 128, 2367-2369.	1.4	16
40	Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. <i>Cancer</i> , 2019, 125, 2656-2665.	4.1	15
41	Survival of patients with gastric lymphoma in Germany and in the United States. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1485-1491.	2.8	13
42	Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2022, 40, 847-854.	1.6	13
43	Survival disparities by age and country of diagnosis for patients with acute leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2787-2792.	1.3	10
44	Outcome disparities by insurance type for patients with acute myeloblastic leukemia. <i>Leukemia Research</i> , 2017, 56, 75-81.	0.8	9
45	Comparison of Emergency Department Wait Times in Adults with Sickle Cell Disease Versus Other Painful Etiologies. <i>Hemoglobin</i> , 2016, 40, 330-334.	0.8	8
46	Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century. <i>Haematologica</i> , 2017, 102, e229-e232.	3.5	8
47	Survival for patients with rare haematologic malignancies: Changes in the early 21st century. <i>European Journal of Cancer</i> , 2017, 84, 81-87.	2.8	8
48	Population-Level Differences in Rectal Cancer Survival in Uninsured Patients Are Partially Explained by Differences in Treatment. <i>Oncologist</i> , 2017, 22, 351-358.	3.7	7
49	Erythropoietin Levels in Patients with Sickle Cell Disease Do Not Correlate with Known Inducers of Erythropoietin. <i>Hemoglobin</i> , 2014, 38, 385-389.	0.8	6
50	Red Cell Alloimmunization in Sickle Cell Disease: Benefit of Extended Crossmatching in Adults. <i>Blood</i> , 2012, 120, 4761-4761.	1.4	6
51	Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. <i>International Journal of Cancer</i> , 2018, 143, 324-332.	5.1	5
52	Long-term survival in chronic myelocytic leukemia after a first primary malignancy. <i>Leukemia Research</i> , 2009, 33, 1604-1608.	0.8	4
53	Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than Internationally. <i>Journal of Clinical Oncology</i> , 2017, 35, 695-696.	1.6	2
54	Erythropoietin Levels in Patients with Sickle Cell Disease Not in Vaso-Occlusive Crisis. <i>Blood</i> , 2012, 120, 3242-3242.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time. <i>Leukemia and Lymphoma</i> , 2022, 63, 1964-1969.	1.3	2
56	Determining the role of smoking in myeloproliferative neoplasms: is it a matter of picking the right control group?. <i>European Journal of Haematology</i> , 2016, 97, 3-4.	2.2	1
57	U.S. Food and Drug Administration Benefitâ€Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. <i>Oncologist</i> , 2019, 24, e188-e195.	3.7	1
58	Influence of insurance type on survival in patients with acute myeloblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17612-e17612.	1.6	1
59	In Reply. <i>Oncologist</i> , 2015, 20, 1224-1224.	3.7	0
60	Ongoing Strong Improvement in Treatment Outcomes for Patients Diagnosed with Non-Hodgkin Lymphoma from the 1990s to the Early 21st Century.. <i>Blood</i> , 2007, 110, 3314-3314.	1.4	0
61	Population Level Survival for Patients with Multiple Myeloma: Variation and Growing Disparity for Patients of Minority Race or Ethnicity. <i>Blood</i> , 2011, 118, 3126-3126.	1.4	0
62	Changes in Survival in Acute Myeloblastic Leukemia by Racial and Ethnic Group: Greater Improvement for Non-Hispanic Whites and Increase in the Disparity for Minority Patients in the Early 21st Century. <i>Blood</i> , 2011, 118, 844-844.	1.4	0
63	Population Level Survival of Patients with Chronic Myeloid Leukemia in Germany in the Early 21st Century. <i>Blood</i> , 2012, 120, 759-759.	1.4	0
64	An International Comparison Of Survival Disparities In Patients With Lymphoma and Myeloma. <i>Blood</i> , 2013, 122, 2925-2925.	1.4	0
65	Survival Disparities By Insurance Type For Patients With Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 1737-1737.	1.4	0
66	Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years. <i>Blood</i> , 2015, 126, 4599-4599.	1.4	0